Search clinical trials for: F18-rhPSMA-7.3

Total 2588 results

Emory University
National Cancer Institute (NCI); Blue Earth Diagnostics

Active, not recruiting

Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma

United States
M.D. Anderson Cancer Center

Completed

An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer

Biochemically Recurrent Prostate Carcinoma | Prostate Adenocarcinoma | Localized Prostate Carcinoma

United States
University of Alabama at Birmingham

Recruiting

18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: A Pilot Study

Prostate Cancer

United States
Blue Earth Diagnostics
Parexel

Completed

Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)

Prostate Cancer

United States, Finland, Netherlands
Blue Earth Therapeutics Ltd
PSI CRO

Recruiting

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Urogenital Neoplasms | Prostatic Neoplasms | Prostatic Diseases | Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | mCRPC

United States, Netherlands
Blue Earth Diagnostics
Parexel

Completed

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)

Prostate Cancer

United States, Finland, Germany, Netherlands
Blue Earth Diagnostics

Completed

Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer

Prostate Cancer

Finland
Northwestern University
National Cancer Institute (NCI)

Recruiting

rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance

Prostate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8

United States
MidLantic Urology
Blue Earth Diagnostics

Recruiting

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

Prostate Cancer

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer

Biochemically Recurrent Prostate Carcinoma | Prostate Adenocarcinoma

United States
Mayo Clinic

Recruiting

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma

United States
Siemens Molecular Imaging

Terminated

Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects

Breast Cancer

United States
St. Paul's Hospital, Canada
Acumed, LLC

Unknown

A Study Comparing Computerized Tomographic Progression of Bone Bridging After Subtalar Fusion Using Fully and Partially Threaded Screws

Subtalar Fusion

Canada
Radboud University Medical Center
ABX advanced biochemical compounds GmbH; Radboud Translational Medicine

Recruiting

F18-PSMA-1007 PET for Early Biochemical Recurrence of Prostate Cancer (PROPER-ABX)

Prostate Cancer Recurrent

Netherlands
NYU Langone Health
Blue Earth Diagnostics

Recruiting

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

Prostate Cancer

United States
Tel-Aviv Sourasky Medical Center

Unknown

Head- to Head Comparison of [68Ga]Ga-PSMA-11 With [18F]PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as Reference-Standard

Prostate Cancer

Israel
Avid Radiopharmaceuticals

Terminated

A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808 (T808)

Alzheimers Disease

United States
Avid Radiopharmaceuticals

Terminated

A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807

Alzheimers Disease | AD

United States
Avid Radiopharmaceuticals

Completed

Augmenting Flortaucipir Dosimetry Estimates

Alzheimer's Disease

United States
Tel-Aviv Sourasky Medical Center

Unknown

The Potential Role of Ga-68-PSMA in Staging, Restaging and Monitoring Response in Primary Liver Cancer: Comparison With F-18-FDG

Hepatocellular Carcinoma (HCC)
Avid Radiopharmaceuticals

Completed

18F-AV-1451 Autopsy Study

Alzheimer's Disease

United States, Australia
Avid Radiopharmaceuticals

Completed

Tau Screening Study in Patients With Early Symptomatic AD

Alzheimer Disease

United States, Canada
Avid Radiopharmaceuticals

Completed

Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

Tau Screening Study in Subjects With Early Symptomatic AD

Alzheimer Disease

United States
University Hospital, Ghent

Completed

Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers

Thyroid Cancer

Belgium
Avid Radiopharmaceuticals

Completed

Flortaucipir PET Imaging in Subjects With FTD

Frontotemporal Dementia

United States
Avid Radiopharmaceuticals

Completed

Clinical Evaluation of Flortaucipir F 18

Depression | Traumatic Brain Injury | Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease

Alzheimer Disease | Mild Cognitive Impairment
Avid Radiopharmaceuticals

Terminated

Flortaucipir 18F PET Imaging in BIOCARD Study

Cognitive Decline

United States
Avid Radiopharmaceuticals
The Cleveland Clinic

Completed

Tau Imaging in Professional Fighters

Alzheimer's Disease

United States
Markus Weber
University Hospital Inselspital, Berne; ETH Zurich

Not yet recruiting

Investigation of Cannabinoid 2-receptor Expression in the Brain and Spine of ALS-patients Compared to Healthy Controls With PET (18F-RoSMALS) (18F-RoSMALS)

Amyotrophic Lateral Sclerosis

Switzerland
Primo Biotechnology Co., Ltd
ABX advanced biochemical compounds GmbH

Recruiting

Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient

Prostate Cancer | Prostate Neoplasm

Taiwan
Johns Hopkins University
National Institute on Aging (NIA)

Withdrawn

Tau Tracer Comparison in Healthy Controls and Alzheimer's Disease Patients

Healthy | Alzheimer Disease

United States
M.D. Anderson Cancer Center
Blue Earth Therapeutics

Recruiting

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

Prostate Cancer

United States
Mayo Clinic

Withdrawn

Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography (PEM-FES)

Breast Neoplasm

United States
Avid Radiopharmaceuticals

Completed

18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy

United States
Assistance Publique Hopitaux De Marseille

Unknown

Can the Assessment of the Subhippocampal Region Contribute to the Detection of Early Diagnosis of Alzheimer's Disease? A Validation Study Using PET With Florbetapir (AV-45).

Alzheimer's Disease

France
Avid Radiopharmaceuticals

Terminated

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

Alzheimer's Disease

United States
The Hospital for Sick Children

Completed

18FDG-PET Imaging to Detect Changes in Airways Inflammation in Cystic Fibrosis Patients

Cystic Fibrosis

Canada
Instituto Tecnologico y de Estudios Superiores...
Tecnologico de Monterrey

Completed

Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia

Hyponatremia
University Health Network, Toronto

Recruiting

Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study

Head and Neck Squamous Cell Carcinoma

Canada
Avid Radiopharmaceuticals

Completed

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects (MCI)

Alzheimer's Disease

United States
University Hospital, Caen

Unknown

Evaluation of the Diagnostic Value of PET (18F-FDG) in Chronic Graft Versus Host Disease (cGVH) (TEP-GVH)

Chronic Graft Versus Host Disease

France
Washington University School of Medicine

Terminated

Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery

Rectal Neoplasms

United States
National Institute of Neurological Disorders and...

Completed

Metabolic Abnormalities in Children With Epilepsy

Seizures | Generalized Epilepsy | Metabolic Disease | Infantile Spasms | Partial Epilepsy

United States
First Hospital of China Medical University

Recruiting

A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma

Multiple Myeloma

China
University of Saskatchewan
Saskatoon Health Region; Sylvia Fedoruk Canadian Centre for Nuclear Innovation

Completed

Registry Type Study to Monitor for Adverse Drug Reactions to Fedoruk Manufactured [F-18]-Fludeoxyglucose

Positron-Emission Tomography and Cone-Beam Computed Tomography
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults

Dengue

United States
Avid Radiopharmaceuticals

Completed

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

Alzheimer Disease

United States
Insel Gruppe AG, University Hospital Bern

Completed

Diagnostic Accuracy and Performance of 18F-PSMA-1007

Prostate Cancer

Switzerland

Search clinical trials for: F18-rhPSMA-7.3

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations